Редактирование: NRM (раздел)

==Publications==

{{medline-entry
|title=Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/31445185
|abstract=Clonal hematopoiesis (CH), characterized by the accumulation of acquired somatic mutations in the blood, is associated with an elevated risk of aging-related diseases and premature mortality in non-cancer populations. Patients who undergo autologous hematopoietic cell transplantation (HCT) are also at high risk of premature onset of aging-related conditions. Therefore, we examined the association between pretreatment CH and late-occurring (≥1 year) nonrelapse mortality ([[NRM]]) after HCT. We evaluated pathogenic and likely pathogenic CH variants (PVs) in 10 patients who developed [[NRM]] after HCT and in 29 HCT recipient controls matched by age at HCT ± 2 years (median, 64.6 years; range, 38.5 to 74.7 years), sex (79.5% male), diagnosis (61.5% with non-Hodgkin lymphoma, 18.0% with Hodgkin lymphoma, and 20.5% with multiple myeloma), and duration of follow-up. We analyzed mobilized hematopoietic stem cell DNA in samples collected before HCT using a custom panel of amplicons covering the coding exons of 79 myeloid-related genes associated with CH. PVs with allele fractions >2% were used for analyses. Cases were significantly more likely than controls to have CH (70% versus 24.1%; P = .002), to have ≥2 unique PVs (60% versus 6.9%; P < .001), and to have PVs with allelic fractions ≥10% (40% versus 3.4%; P = .003). Here we provide preliminary evidence of an association between pre-HCT CH and [[NRM]] after HCT independent of chronologic age. Integration of CH analyses may improve the accuracy of existing pre-HCT risk prediction models, setting the stage for personalized risk assessment strategies and targeted treatments to optimally prevent or manage late complications associated with HCT.
|mesh-terms=* Adult
* Age Factors
* Aged
* Aging
* Autografts
* Female
* Hematopoiesis
* Hematopoietic Stem Cell Transplantation
* Humans
* Lymphoma, Non-Hodgkin
* Male
* Middle Aged
* Multiple Myeloma
* Retrospective Studies
|keywords=* Autologous
* Clonal hematopoiesis
* Lymphoma
* Multiple myeloma
* Nonrelapse mortality
* Survivors
* Transplantation
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192097
}}
{{medline-entry
|title=Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/23361908
|abstract=Older patients are increasingly undergoing allogeneic hematopoietic transplantation. A relevant question is whether outcomes can be improved with a younger allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched sibling (MSD). Accordingly, transplants in leukemia/lymphoma patients age ≥50 years were analyzed comparing outcomes for recipients of MSD ≥50 (n = 1415) versus MUD <50 years (n = 757). Risks of acute graft-versus-host disease (GVHD) grade 2 to 4 (hazard ratio [HR], 1.63; P < .001), 3 to 4 (HR, 1.85; P < .001), and chronic GVHD (HR, 1.48; P < .0001) were higher after MUD compared with MSD transplants. The effect of donor type on nonrelapse mortality ([[NRM]]), relapse, and overall mortality was associated with performance score. For patients with scores of 90 or 100, [[NRM]] (HR, 1.42; P = .001), relapse (HR, 1.45; P < .001), and overall mortality (HR, 1.28; P = .001) risks were higher after MUD transplants. For patients with scores below 90, [[NRM]] (HR, 0.96; P = .76), relapse (HR, 0.86; P = .25), and overall mortality (HR, 0.90; P = .29) were not significantly different after MUD and MSD transplants. These data favor an MSD over a MUD in patients age ≥50 years.
|mesh-terms=* Age Factors
* Aged
* Aging
* Blood Grouping and Crossmatching
* Cohort Studies
* Donor Selection
* Female
* Hematopoietic Stem Cell Transplantation
* Human Experimentation
* Humans
* Male
* Middle Aged
* Retrospective Studies
* Siblings
* Transplantation, Homologous
* Unrelated Donors

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612864
}}